Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT.
Author
Machowicz, RafalSuarez, Felipe
Wiktor-Jedrzejczak, Wieslaw
Eikema, Diderik-Jan
de Wreede, Liesbeth C
Blok, Henric-Jan
Isaksson, Cecilia
Einsele, Hermann
Poiré, Xavier
van Dorp, Suzanne
Nikolousis, Emmanouil
Johansson, Jan-Erik
Kobbe, Guido
Zecca, Marco
Arnold, Renate
Gerbitz, Armin
Finke, Jürgen
Díez-Martín, Jose Luis
Bonifazi, Francesca
McQuaker, Grant
Lenhoff, Stig
Rohrlich, Pierre-Simon
Theobald, Matthias
Ljungman, Per
Collin, Matthew
Albert, Michael H
Ehninger, Gerhard
Carlson, Kristina
Halaburda, Kazimierz
Lehmberg, Kai
Schönland, Stefan
Yakoub-Agha, Ibrahim
Gennery, Andrew R
Lankester, Arjan C
Kröger, Nicolaus
Publication date
2022-03-24Subject
Haematology
Metadata
Show full item recordAbstract
Hemophagocytic lymphohistiocytosis (HLH; hemophagocytic syndrome) is a rare syndrome of potentially fatal, uncontrolled hyperinflammation. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is indicated in primary, recurrent or progressive HLH, but information about its outcomes in the adult population is limited. We obtained data about 87 adult (≥18 years of age) patients retrospectively reported to the EBMT. The median survival time was 13.9 months. The three and five-year overall survival (OS) was 44% (95% CI 33-54%). Among 39 patients with a follow-up longer than 15 months, only three died. Relapse rate was 21% (95% CI 13-30%), while NRM reached 36% (95% CI 25-46%). Younger patients (<30 years of age) had better prognosis, with an OS of 59% (95% CI 45-73%) at three and five years vs 23% (95% CI 8-37%) for older ones. No difference in survival between reduced and myeloablative conditioning was found. To our knowledge, this is the largest report of adult HLH patients who underwent allo-HSCT. Patients who survive the first period after this procedure can expect a long disease-free survival. Both reduced intensity and myeloablative conditioning have therapeutic potential in adult HLH.Citation
Machowicz R, Suarez F, Wiktor-Jedrzejczak W, Eikema DJ, de Wreede LC, Blok HJ, Isaksson C, Einsele H, Poiré X, van Dorp S, Nikolousis E, Johansson JE, Kobbe G, Zecca M, Arnold R, Gerbitz A, Finke J, Díez-Martín JL, Bonifazi F, McQuaker G, Lenhoff S, Rohrlich PS, Theobald M, Ljungman P, Collin M, Albert MH, Ehninger G, Carlson K, Halaburda K, Lehmberg K, Schönland S, Yakoub-Agha I, Gennery AR, Lankester AC, Kröger N. Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT. Bone Marrow Transplant. 2022 May;57(5):817-823. doi: 10.1038/s41409-022-01634-5. Epub 2022 Mar 24Type
ArticleAdditional Links
http://www.nature.com/bmt/PMID
35332305Journal
Bone Marrow TransplantationPublisher
Nature Publishing Groupae974a485f413a2113503eed53cd6c53
10.1038/s41409-022-01634-5